Abstract
Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.
Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.
Current Pharmaceutical Design
Title:Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Volume: 27 Issue: 25
Author(s): Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang and Xiaohui Zhou*
Affiliation:
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198,China
Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.
Abstract: Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.
Export Options
About this article
Cite this article as:
Aktar Nasrin, Moudud Ahmed, Chen Tingting , Gao Xiaoqing , Min Hanhui , Tang Meng and Zhou Xiaohui *, Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome, Current Pharmaceutical Design 2021; 27 (25) . https://dx.doi.org/10.2174/1381612827666210322125054
DOI https://dx.doi.org/10.2174/1381612827666210322125054 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Despite an Extensive Sequence Analysis Identification of Functional Candidates Amongst Hypothetical Proteins of Neisseria gonorrhoeae
Letters in Drug Design & Discovery Nano-Tetrandrine Efficiently Inhibits the Proliferation and Induces the Apoptosis of Hep2 Cells through a Mitochondrial Signaling Pathway
Current Signal Transduction Therapy Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients
Mini-Reviews in Medicinal Chemistry Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Current Pharmaceutical Design Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Effect of Pregnenolone Derivatives on the Selective Inhibition of 5α-Reductase 2 Activity
Current Enzyme Inhibition Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Cytotoxic Activity and Inhibition of Tumor Cell Invasion by Derivatives of a Chemically Modified Tetracycline CMT-3 (COL-3)
Current Medicinal Chemistry DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets